WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Nottingham stabbing victim Grace O'Malley
Former Labour minister Frank Field dies from cancer aged 81: Tributes pour in for 'formidable' ex
How YOU can lower your council tax by challenging it
More than 1 in 4 US adults over age 50 say they expect to never retire, an AARP study finds
Former Spain coach Del Bosque to head the commission overseeing beleaguered soccer federation
The human foods that could be making your dog fat, revealed
The body types that raise the risk of colon cancer
The body types that raise the risk of colon cancer
Immigrant's $1.3B Powerball win spotlights the Iu Mien community
How YOU can lower your council tax by challenging it
Paris Olympic athletes to feast on freshly baked bread, select cheeses and plenty of veggie options
Olympic tennis champion Belinda Bencic announces the birth of her daughter